Remogliflozin etabonate
Remogliflozin, a novel, highly selective inhibitor of sodium-glucose cotransporter subtype 2 (SGLT2)Type 2 diabetes mellitus
oral; 100mg twice a day
Hypersensitivity
Paediatric: Safety and efficacy in pediatric patients have not been established Pregnancy: Data not sufficient Lactation: Data not sufficient Elderly: Data not sufficient
Low blood sugar (hypoglycemia), Urinary tract infections, Nervousness or anxiety, Irritability to sweat, Weight loss, Dizziness or headache, Fatigue, genital fungal infection
other hypoglycemic drugs
Brand Name | Manufactured by |
---|---|
REFOZI-M | CARDIMIND PHARMACEUTICALS (A Division of Asterisk Laboratories Pvt Ltd) |